Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01068418|
Recruitment Status : Completed
First Posted : February 15, 2010
Results First Posted : February 14, 2017
Last Update Posted : March 30, 2017
Hypothesis: Vitamin D supplementation lower renin-angiotensin system activity in obesity.
Specific Aim: To investigate whether Vitamin D supplementation in obesity improves the vascular sensitivity to angiotensin II.
|Condition or disease||Intervention/treatment||Phase|
|Obesity Vitamin D Deficiency Hypertension||Dietary Supplement: Vitamin D (cholecalciferol)||Not Applicable|
Vitamin D deficiency and obesity are international epidemics that have both been associated with increased activity of the renin-angiotensin system (RAS). Because increased RAS activity is associated with cardiovascular disease, interventions to lower RAS will have favorable public health impacts.
This study aims to evaluate whether the supplementation of Vitamin D in obese subjects will lower local tissue RAS activity. RAS activity will be evaluated by cross-sectional measurement of RAS components and by quantifying the vascular response to an infusion of angiotensin II. Subjects will be studied while Vitamin D deficient, and will return for repeat study following Vitamin D supplementation, for comparison.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||26 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Vitamin D Deficiency Augments Renin-Angiotensin System Activity in Obesity|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||September 2011|
|Actual Study Completion Date :||September 2011|
Experimental: Vitamin D3
15000IU of vitamin D3 daily: open-label, single-arm
Dietary Supplement: Vitamin D (cholecalciferol)
cholecalciferol 15,000 IU daily for 30 days
- The Change in the Mean Arterial Blood Pressure in Response to an Infusion of Angiotensin II [ Time Frame: baseline and 1 month following vitamin D3 therapy ]
- The Change in Renal Blood Flow in Response to an Infusion of Angiotensin II [ Time Frame: baseline and 1 month following vitamin D3 therapy ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01068418
|United States, Massachusetts|
|Brigham and Women's Hospital|
|Boston, Massachusetts, United States, 02115|
|Principal Investigator:||Jonathan S Williams, MD, MMSc||Brigham and Women's Hospital|
|Study Director:||Anand Vaidya, MD||Brigham and Women's Hospital|